Assured Guaranty (NYSE:AGO) reported a stronger start to 2026 in new business production, with management pointing to higher demand across U.S. public finance, non-U.S. public finance and global structured finance, while also signaling a near-term slowdown in share repurchases as it allocates capita
Ares Commercial Real Estate (NYSE:ACRE) reported a first-quarter loss as higher credit reserves tied to two large troubled loans weighed on results, while management said it continued to reshape the portfolio through new originations, asset resolutions and reduced office exposure.
Chief Executive O
Arbor Realty Trust (NYSE:ABR) executives said the company is making progress reducing troubled assets but warned that higher long-term rates are extending the timeline for resolutions and weighing on earnings.
On the company’s first-quarter 2026 earnings call, President and Chief Executive Officer
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent fi
Ziff Davis (NASDAQ:ZD) reported a modest decline in first-quarter 2026 revenue from continuing operations, while management emphasized a broader shift in capital allocation that includes stock repurchases, selective acquisitions and potential asset monetization.
Chief Executive Officer Vivek Shah s
Xometry (NASDAQ:XMTR) reported accelerating first-quarter 2026 growth and raised its full-year outlook, citing stronger marketplace activity, expanding buyer adoption and operating leverage across its AI-driven custom manufacturing platform.
Chief Executive Officer Randy Altschuler said the quarter
Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology and immunology pipeline and pointed to multiple upcoming regulatory and clinical milestones.
On the
Zymeworks (NASDAQ:ZYME) reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across its antibody-drug conjugate pipeline and continued share repurchases.
Chair and CEO Ken Galbraith
